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Viewpoint
Discussing treatment burden
Treatment burden is defined as “the workload of 
healthcare and its effect on patient functioning and 
well-being” [1, 2]. It has also been defined as “the 
self-care practices that patients with chronic illness 
must perform to respond to the requirements of 
their healthcare providers, as well as the impact 
that these practices have on patient functioning 
and well-being” [3]. In this issue of Breathe, there 
are several articles addressing treatment burden 
from different perspectives. This Viewpoint article 
focusses on the discussions between the patient 
and their healthcare professional (HCP). What 
are the important topics to cover in discussions 
about treatment burden? What are the barriers to 
these discussions? What facilitates a productive 
conversation about treatment burden? The authors 
of this article include three patients (with asthma, 
COPD and idiopathic pulmonary fibrosis (IPF), four 
HCPs representing different specialties (primary 
care, secondary and tertiary care, nursing and 
pharmacy) and a representative of the European 
Lung Foundation (ELF). This article is based on a 
video discussion between the authors; it was then 
refined via e-mail by all the authors.
What key factors about 
treatment burden 
should be discussed 
during a consultation 
when medications are 
being prescribed?
Disease trajectory related to 
medicines
From the outset of any discussion regarding 
medication, it is important to relate it to the 
patient’s diagnosed condition and to avoid 
medical jargon. It may not be possible to cure 
the condition, but the HCPs should explain the 
realistic aims of treatment, manage the patient’s 
expectations and suggest strategies to enable the 
patient to manage their condition and improve 
their quality of life. Crucially, the patient needs to 
be told if this requires using medicines regularly 
and at specific hours of the day and/or making 
changes to lifestyle and work-related activities. It is 
equally important to highlight the implications if 
no changes are made (e.g. if the patient continues 
to smoke). Patients may need to be aware that 
some treatments are life-long, and that stopping 
or modifying treatment could result in worsening 
of their condition.
Potential benefits of treatment
It is helpful to discuss broadly what treatments 
are available to the patient (both pharmacological 
and non-pharmacological) with the aim of 
personalising the approach to the individual. 
Understanding the patient’s perception of the 
severity of their condition, their expectations 
from treatment and the magnitude of potential 
benefits is important. For example, some 
patients may not take medication as intended 
(or at all), believing that their condition is not 
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serious or that they have little to gain. This may 
be particularly difficult when the benefits (e.g. 
having no immediate change in symptoms with 
preventative treatment, such as in asthma) are 
not immediately apparent but adherence to early 
treatment results in better long-term outcomes. 
Burden is relevant and may be a trade-off: for 
example, a patient may be willing to take several 
pills a day if their condition is serious, but not if 
they consider their condition to be mild. HCPs 
should communicate the potential treatment 
benefits and relevant treatment timeframe in a 
way that the patient can understand, accounting 
for any learning (or other) disability/language 
barriers, in order to ensure that the patient has 
a clear understanding and can work closely with 
their HCP to commit to the treatment targets.
Potential side effects and 
impact on quality of life
Any medication prescribed should be the “best fit” 
for the patient. To reach this decision, the patient 
must understand the medication’s potential side 
effects so they can weigh up the possible impact 
on their quality of life. A good example of this 
is in IPF, for which the two available antifibrotic 
drugs have very different side effects and the 
choice may depend on the patient’s assessment 
of the likely impact of side effects. It is vital that 
patients know who to contact to discuss concerns 
(and how to do so) and for practical advice on 
how to manage side effects. Similarly, regular 
monitoring, especially in the early stages ensures 
that side effects are recognised promptly and 
managed efficiently. In patients who, themselves, 
have barriers to understanding (young children or 
patients with severe cognitive impairment), it is 
important to have this conversation with their 
carer(s) whilst involving the patient to the extent 
that understanding allows.
The possibility to stop 
ineffective treatments
A treatment “trial” can be carried out with 
agreement to stop the medication if clinical goals 
are not achieved and/or benefit is not felt by the 
patient within a specific timeframe. Realistic 
treatment goals of a new medication must be 
clearly defined for both the patient and the HCP, 
recognising that the patient’s perception of benefit 
may differ from a clinical definition of effectiveness. 
A patient, for example, may want to improve day-
to-day function or to prioritise extended life, while 
the HCP may judge effectiveness as a change in 
physiological parameters. More generally, all 
medicines should be reviewed regularly (annually as 
a minimum) to check that they are still appropriate 
and to ensure their usage remains meaningful for 
the patient.
Practicalities
The HCP should explore the patient’s perceptions 
and barriers to adopting interventions (both 
medicine and any other recommendations). Does it 
fit with their daily routines? Can the dosage regimen 
be simplified to avoid a complex schedule with 
many and/or frequent medicines? It is important 
that the HCP and patient work in partnership to 
dispel myths and agree a way forward that fits with 
both the patient’s medical needs and their lifestyle 
and working routine.
The method of administration (e.g. tablet, 
injection, inhaler) may be important to the patient. 
It needs to be practical, convenient and acceptable, 
and as consistent as possible. For example, if an 
inhaler device is changed the patient has to be 
re-educated on how to take the medication to 
minimise the risk of sub-optimal technique.
Access to medication
Some medications are only available from a 
specialist. Arrangements for repeat prescribing can 
create additional burdens on the patient, especially if 
the specialist care centre is far from home or specific 
monitoring of the patient is required. This has been 
especially relevant during the coronavirus disease 
2019 (COVID-19) pandemic due to limitations to 
accessing healthcare facilities. Close collaboration 
between primary and specialist care and e-health 
technologies can be used to minimise patient burden 
in requesting and receiving repeat prescriptions.
Although cost may not be an issue that is 
discussed during a consultation, the HCP should 
be aware whether their patient will have to pay for 
prescriptions (and this may vary from condition to 
condition and country to country), as this can be 
a significant barrier for some patients. Financial 
constraints preventing the patient’s access to 
medication may be addressed with the help of 




Polypharmacy is the situation of having many 
medications (or many different forms of medicine, 
e.g. inhalers, tablets, patches and liquids), which adds 
to the treatment burden for a patient. Polypharmacy 
is sometimes necessary but, if additional medication 
is recommended, the reasons should be clearly 
explained to the patients and, if appropriate, another 
medication should be stopped. Tools such as “STOPP-
START” (Screening Tool of Older Persons’ Prescriptions 
and Screening Tool to Alert to Right Treatment) may be 
considered as a guide to de-prescribing [4, 5]. These 
tools offer criteria to help HCPs to review potentially 
inappropriate medications in the elderly and have been 
endorsed as best practice by some organisations.
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Many patients have multimorbidity, and HCPs 
should always discuss potential interactions of the 
medication being prescribed with other treatments. 
This may require colleagues working in primary care 
to mediate between multiple specialists. Patients 
can be very concerned about possible interactions 
between the different medications that they are 
taking. Just explaining that computer prescribing 
software generates warnings and that this will 
be flagged up and considered by the HCP can be 
reassuring. In countries where computer software 
is not available, HCPs need to ensure a different 
safety net is in place to avoid interaction risks. 
Interactions between patient factors (e.g. renal/liver 
function, disability, attitude to risk, experience of 
illness, values/beliefs and social circumstances) and 
medicine can be avoided by a pharmacist’s check to 
reduce and mitigate unnecessary risk to patients.
Non-pharmacological 
interventions
Non-pharmacological interventions, such as 
pulmonary rehabilitation, breathing retraining or 
social prescribing (e.g. attending a gym), may help 
reduce pharmacological treatment burden for 
a patient. These should always be considered as 
adjuncts to conventional therapy where possible. 
On some occasions, patients wish to discuss non-
pharmacological interventions deriving from their 
cultural backgrounds or internet searches. HCPs 
need to gather information from the patient and be 
cautious about considering these options as well as 
ensuring they are safe and suitable for the patient.
Signposting to reputable 
resources of information
Patients can now access information in many 
different ways about their condition and their 
treatment. To ensure that they use trustworthy 
and reliable information, the HCP should signpost 
patients to organisations and websites where they 
can find reliable evidence-based information.
What are the barriers 
to discussions about 
treatment burden?
One of the major barriers for both HCPs and patients 
is the (limited) time available during consultations, 
which makes detailed discussions on treatment 
burden difficult. HCPs should be prepared to 
recommend further sources of reliable information. 
For example, support groups (where they exist) 
can provide a supportive environment in which to 
share experiences (e.g. of side effects) with other 
patients and allow extended time for discussion 
and feedback.
The official “patient information leaflets” (PILs) 
that accompany medication ought to be useful 
sources of information, but patients are often put off 
by the long list of adverse side effects and by a lack 
of balanced information about risks and benefits. A 
particular issue which causes anxiety and concern 
for patients is that the PIL may not give information 
on unlicensed uses of the medicine. HCPs should 
pre-empt this, explain any discrepancies and not rely 
on these leaflets as the sole source of information 
for patients on their medication. Some patient 
organisations publish leaflets on key medications 
with input from HCPs.
For patients
Patients may lack the knowledge, understanding, 
skills and confidence to use health information 
effectively. HCPs need to take this into account 
by providing information in a form and format 
patients can understand, preferably in their native 
language. They should also address specific barriers, 
such as learning disabilities and reduced physical/
functional/cognitive capacity, which mean patients 
may struggle to comprehend the information being 
provided. Conversely, there can be challenges 
associated with “expert patients” who have set ideas 
and specific (sometimes unrealistic) expectations, 
which prohibit an open conversation with the HCP.
Patients may fear being blamed by the HCP; 
for example, for being a smoker or overweight. 
They may feel guilt or shame for not taking the 
medication that has been prescribed to them. A 
non-judgmental relationship and rapport between 
the HCP and patient is vital, allowing patients to 
explain about the treatment burden, the difficulties 
they have with regular medication or the reason 
that they have chosen to discontinue medication. 
HCPs should be careful with the language used in 
these discussions. Other factors that might act as 
a barrier for patients to discuss treatment burden 
include lack of self-efficacy, demotivation and lack 
of confidence.
One final point highlighted by patients, is that 
it can be really difficult to listen to details about 
medication when trying to take in and process the 
enormity of a diagnosis of a life-limiting disease 
such as IPF (which has a 3–5 year prognosis) or 
cancer. Patients who are worried about their disease 
are often unable to listen well and may not fully 
absorb the information provided or think to raise 
issues of concern. Taking a friend or family member 
into a consultation can help to ensure that the 
patient has someone supporting them, listening 
to information discussed and prompting the patient 
to ask questions or explain their worries.
For HCPs
Offering choice can be difficult for HCPs who are 
often limited in what they can prescribe by the need 
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to follow guidelines or organisational constraints 
related to cost or medication availability in their 
settings.
HCPs may lack training in communication skills 
or would benefit from learning techniques such as 
motivational interviewing. Such communication 
skills should be a fundamental component of 
all medical, nursing or other HCP training and 
continued medical education (CME).
There is often a lack of integration in 
healthcare systems, which is exacerbated by 
poor IT infrastructure. This can result in different 
specialists not having complete information 
about the patient when reviewing them. In some 
countries, primary and specialist care are not 
linked through IT systems and information cannot 
be shared in real time. It is essential that all HCPs 
treating a patient are informed about other aspects 
of their care. This is particularly true with patients 
who have other chronic conditions.
How to have a productive 
discussion about 
treatment burden
There have been many points highlighted here 
that can help HCPs and patients to discuss the 
issue of treatment burden. There have also been a 
number of publications on the topic [6, 7]. Table 1 
outlines the top tips from the authors of this paper 
to facilitate productive conversation.
Conclusion
There are many aspects of treatment burden that 
should be considered by HCPs when prescribing 
new medications to patients. These include having 
a common understanding of the goals of treatment, 
the risk of adverse side effects and potential impact 
Table 1 Tops tips for discussion between the healthcare professional and the patient about treatment burden
For the patient For the healthcare professionals
Prepare questions and practice explaining about 
concerns before your consultation
Patients with chronic conditions have to adjust to the implications 
of the diagnosis on their life and lifestyle. Be sensitive with how you 
communicate this
Take a carer or friend with you to consultations. Brief 
them about your questions and concerns and ask 
them to help listen to the information provided
Encourage the patient to bring a companion; and encourage them to write 
down key information
Think about treatment goals and be clear what is 
important to you (e.g. being less breathless, being 
able to run)
Discuss lifestyle behaviours of the patient: what are their priorities? This 
will help to guide the best medication, taking into account issues such as 
side-effects, monitoring requirements, cost, impact on driving and family
Ask for the names of other HCPs (e.g. specialist 
nurse) who you can discuss this with in more detail 
in the future
Provide details, where possible, for a nurse or pharmacist who will have the 
time to have a longer/further discussion with the patient; but ensure the 
messages are consistent
Ensure that you understand why a treatment is being 
recommended and ask for further information to 
help you make decisions about this if required
Explain clearly what treatments are available so patients can make an 
informed choice. Remember that limited health literacy is common even 
without specific challenges or learning disabilities
Read and learn from trusted/reputable resources. 
Ask about good sources of information
Provide the patient with details of a trusted patient organisation or peer-
support group from which they can gain input and further advice
Ask about side-effects, and about how likely they 
are to happen. Check what you should do if you are 
experiencing a side-effect
Do not wait to be asked about side-effects. Tell patients about anything 
common or potentially serious and ensure they know what to do if a 
problem develops
Explain any factors that you feel may make it 
harder for you to take your medicines or follow the 
treatment recommendations given
Explore non-adherence in a non-judgemental way to agree with the patient 
how to gain benefit from treatment, personalised to the individual’s 
circumstances
Ask if you think that one of your medications is no 
longer needed or is causing side-effects
Agree with the patient if specific medications can be stopped or regime 
modified (using tools such as STOPP/START). Regularly review treatments 
to de-prescribe, if appropriate
Ask about written information (such as action plans) 
that could help you follow advice
Provide simple, written follow-up advice, including self-management plans 
(e.g. asthma action plans [8]), which can empower patients to be partners 
in their care
Medication reviews are important for safe use of 
medications – use them to discuss any concerns 
that you have about your treatment
Using a qualitative measure of treatment burden at annual reviews could 
offer an opportunity to raise issues that are bothering the patient [9]
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on lifestyle. Healthcare professionals should 
help patients to reach informed decisions about 
treatments in order to maximise benefits while 
minimising the treatment burden.
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Key points
●● There are many aspects of treatment burden that should be considered by healthcare professionals 
(HCPs) when prescribing new medications to patients. These include having a common understanding 
of the (realistic) goals of treatment, the risk of side-effects and the potential impact on lifestyle.
●● Major barriers to the discussion of treatment burden include lack of time, limited understanding 
on the part of the patient, and limited communication skills and understanding of the patient’s 
perspective by the HCP.
●● Patients and HCPs should prepare for a discussion about new medications to ensure that the 
burden of treatment can be minimised.
